Analgesics Market Size Analysis 2022 To 2030

The global analgesics market size accounted for US$ 105.8 Bn in 2021 and is projected to reach around USD 149.3 Bn by 2030, growing at a CAGR of 3.9% from 2022 to 2030.

Analgesics Market Key Takeaways:

• North America region has accounted 42.3% revenue share in 2021.
• Asia Pacific region is expected to grow at a CAGR of 7.8% from 2022 to 2030.
• By drug type, the NSAID’s segment is expected to reach at a CAGR of 4.5% from 2022 to 2030.
• By indication, the surgical pain has held revenue share of over 53.5% in 2021. However, the intravenous segment is expected to grow at a CAGR of 7.7% from 2022 to 2030
• By type, prescription segment has accounted 71% revenue share in 2021.
• By route of administration, the oral segment has 48% revenue share in 2021.

Report Summary

The global analgesics market report provides a Point-by-Point and In-Depth analysis of global market size, regional and country-level market size, market share, segmentation market growth, competitive landscape, sales analysis, opportunities analysis, strategic market growth analysis, the impact of domestic and global market key players, value chain optimization, trade regulations, recent developments, product launches, area marketplace expanding, and technological innovations.

The study offers a comprehensive analysis on diverse features, including production capacities, demand, product developments, revenue generation, and sales in the analgesics market across the globe.

A comprehensive estimate on the analgesics market has been provided through an optimistic scenario as well as a conservative scenario, taking into account the sales of analgesics during the forecast period. Price point comparison by region with global average price is also considered in the study.

Analgesics Market Scope

Key Highlights:

Reports Coverage: It incorporates key market sections, key makers secured, the extent of items offered in the years considered, worldwide containerized analgesics market and study goals. Moreover, it contacts the division study gave in the report based on the sort of item and applications.

Market Outline: This area stresses the key investigations, market development rate, serious scene, market drivers, patterns, and issues notwithstanding the naturally visible pointers.

Market Production by Region: The report conveys information identified with import and fare, income, creation, and key players of every single local market contemplated are canvassed right now.

Also Read: Immune Checkpoint Inhibitors Market Size Analysis 2022 To 2030

Analgesics Market Players

The report includes the profiles of key analgesics market companies along with their SWOT analysis and market strategies. In addition, the report focuses on leading industry players with information such as company profiles, components and services offered, financial information, key development in past five years.

Major companies operating in this area are Abbott, Pfizer Inc., Eli Lilly & Company, Endo International plc, F. Hoffmann-La Roche AG Bausch Health Companies Inc., Merck & Co. Inc., AbbVie Inc., Novartis AG, Johnson & Johnson Private Limited, GSK plc., Purdue Pharma L.P.

Market Segmentation

By Drug Class

• Opioids
  • Morphine
  • Fentanyl
  • Codiene
  • Methadone
  • Meperidine
  • Oxycodone
  • Tramadol
  • Dextromethorphan
  • Buprenorphine
  • Others
• NSAIDs
• Local Anesthetics
• Acetaminophen

By Indication

• Surgical Pain
• Cancer Pain
• Neuropathic Pain
• Others

By Type

• Prescription
• OTC

By Pain Type

• Musculoskeletal Pain
• Surgical and Trauma Pain
• Cancer Pain
• Neuropathic Pain
• Migraine
• Obstetrical Pain
• Fibromyalgia
• Pain due to Burns
• Dental/Facial Pain
• Paediatric Pain
• Others

By Application

• Internal Analgesics
• External Analgesics

By Route of Administration

• Oral
• Parenteral
• Transdermal
• Others

By Distribution Channel

• Hospital pharmacies
• Retail pharmacies
• Drug Stores
• Online pharmacies

Regional Segmentation

• North America (U.S., Canada, Mexico)
• Europe (Germany, France, U.K., Italy, Spain, Rest of Europe)
• Asia-Pacific (China, Japan, India, Southeast Asia and Rest of APAC)
• Latin America (Brazil and Rest of Latin America)
• Middle East and Africa (GCC, North Africa, South Africa, Rest of MEA)

Research Methodology

Secondary Research

It involves company databases such as Hoover’s: This assists us to recognize financial information, the structure of the market participants and industry’s competitive landscape.

The secondary research sources referred in the process are as follows:

• Governmental bodies, and organizations creating economic policies
• National and international social welfare institutions
• Company websites, financial reports and SEC filings, broker and investor reports
• Related patent and regulatory databases
• Statistical databases and market reports
• Corporate Presentations, news, press release, and specification sheet of Manufacturers

Primary Research

Primary research includes face-to-face interviews, online surveys, and telephonic interviews.

• Means of primary research: Email interactions, telephonic discussions and Questionnaire-based research etc.
• In order to validate our research findings and analysis, we conduct primary interviews of key industry participants. Insights from primary respondents help in validating the secondary research findings. It also develops Research Team’s expertise and market understanding.

TABLE OF CONTENT

Chapter 1. Introduction

1.1. Research Objective

1.2. Scope of the Study

1.3. Definition

Chapter 2. Research Methodology

2.1. Research Approach

2.2. Data Sources

2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope 

4.1. Introduction

4.2. Market Classification and Scope

4.3. Industry Value Chain Analysis

4.3.1. Raw Material Procurement Analysis

4.3.2. Sales and Distribution Channel Analysis

4.3.3. Downstream Buyer Analysis

Chapter 5. Market Dynamics Analysis and Trends

5.1. Market Dynamics

5.1.1. Market Drivers

5.1.2. Market Restraints

5.1.3. Market Opportunities

5.2. Porter’s Five Forces Analysis

5.2.1. Bargaining power of suppliers

5.2.2. Bargaining power of buyers

5.2.3. Threat of substitute

5.2.4. Threat of new entrants

5.2.5. Degree of competition

Chapter 6. Competitive Landscape

6.1.1. Company Market Share/Positioning Analysis

6.1.2. Key Strategies Adopted by Players

6.1.3. Vendor Landscape

6.1.3.1. List of Suppliers

6.1.3.2. List of Buyers

Chapter 7. Global Analgesics Market, By Drug Class

7.1. Analgesics Market, by Drug Class, 2022-2030

7.1.1. Opioids

7.1.1.1. Market Revenue and Forecast (2017-2030)

7.1.2. NSAIDs

7.1.2.1. Market Revenue and Forecast (2017-2030)

7.1.3. Local Anesthetics

7.1.3.1. Market Revenue and Forecast (2017-2030)

7.1.4. Acetaminophen

7.1.4.1. Market Revenue and Forecast (2017-2030)

Chapter 8. Global Analgesics Market, By Indication

8.1. Analgesics Market, by Indication, 2022-2030

8.1.1. Surgical Pain

8.1.1.1. Market Revenue and Forecast (2017-2030)

8.1.2. Cancer Pain

8.1.2.1. Market Revenue and Forecast (2017-2030)

8.1.3. Neuropathic Pain

8.1.3.1. Market Revenue and Forecast (2017-2030)

8.1.4. Others

8.1.4.1. Market Revenue and Forecast (2017-2030)

Chapter 9. Global Analgesics Market, By Type

9.1. Analgesics Market, by Type, 2022-2030

9.1.1. Prescription

9.1.1.1. Market Revenue and Forecast (2017-2030)

9.1.2. OTC

9.1.2.1. Market Revenue and Forecast (2017-2030)

Chapter 10. Global Analgesics Market, By Pain Type

10.1. Analgesics Market, by Pain Type, 2022-2030

10.1.1. Musculoskeletal Pain

10.1.1.1. Market Revenue and Forecast (2017-2030)

10.1.2. Surgical and Trauma Pain

10.1.2.1. Market Revenue and Forecast (2017-2030)

10.1.3. Cancer Pain

10.1.3.1. Market Revenue and Forecast (2017-2030)

10.1.4. Neuropathic Pain

10.1.4.1. Market Revenue and Forecast (2017-2030)

10.1.5. Migraine

10.1.5.1. Market Revenue and Forecast (2017-2030)

10.1.6. Obstetrical Pain

10.1.6.1. Market Revenue and Forecast (2017-2030)

10.1.7. Fibromyalgia

10.1.7.1. Market Revenue and Forecast (2017-2030)

10.1.8. Pain due to Burns

10.1.8.1. Market Revenue and Forecast (2017-2030)

10.1.9. Dental/Facial Pain

10.1.9.1. Market Revenue and Forecast (2017-2030)

10.1.10. Paediatric Pain

10.1.10.1. Market Revenue and Forecast (2017-2030)

10.1.11. Others

10.1.11.1. Market Revenue and Forecast (2017-2030)

Chapter 11. Global Analgesics Market, By Application

11.1. Analgesics Market, by Application, 2022-2030

11.1.1. Internal Analgesics

11.1.1.1. Market Revenue and Forecast (2017-2030)

11.1.2. External Analgesics

11.1.2.1. Market Revenue and Forecast (2017-2030)

Chapter 12. Global Analgesics Market, By Route of Administration

12.1. Analgesics Market, by Route of Administration, 2022-2030

12.1.1. Oral

12.1.1.1. Market Revenue and Forecast (2017-2030)

12.1.2. Oral

12.1.2.1. Market Revenue and Forecast (2017-2030)

12.1.3. Transdermal

12.1.3.1. Market Revenue and Forecast (2017-2030)

12.1.4. Others

12.1.4.1. Market Revenue and Forecast (2017-2030)

Chapter 13. Global Analgesics Market, By Distribution Channel

13.1. Analgesics Market, by Distribution Channel, 2022-2030

13.1.1. Hospital pharmacies

13.1.1.1. Market Revenue and Forecast (2017-2030)

13.1.2. Retail pharmacies

13.1.2.1. Market Revenue and Forecast (2017-2030)

13.1.3. Drug Stores

13.1.3.1. Market Revenue and Forecast (2017-2030)

13.1.4. Online pharmacies

13.1.4.1. Market Revenue and Forecast (2017-2030)

Chapter 14. Global Analgesics Market, Regional Estimates and Trend Forecast

14.1. North America

14.1.1. Market Revenue and Forecast, by Drug Class (2017-2030)

14.1.2. Market Revenue and Forecast, by Indication (2017-2030)

14.1.3. Market Revenue and Forecast, by Type (2017-2030)

14.1.4. Market Revenue and Forecast, by Pain Type (2017-2030)

14.1.5. Market Revenue and Forecast, by Application (2017-2030)

14.1.6. Market Revenue and Forecast, by Distribution Channel (2017-2030)

14.1.7. Market Revenue and Forecast, by Route of Administration (2017-2030)

14.1.8. U.S.

14.1.8.1. Market Revenue and Forecast, by Drug Class (2017-2030)

14.1.8.2. Market Revenue and Forecast, by Indication (2017-2030)

14.1.8.3. Market Revenue and Forecast, by Type (2017-2030)

14.1.8.4. Market Revenue and Forecast, by Pain Type (2017-2030)

14.1.8.5. Market Revenue and Forecast, by Application (2017-2030)

14.1.8.6. Market Revenue and Forecast, by Distribution Channel (2017-2030)

14.1.8.7. Market Revenue and Forecast, by Route of Administration (2017-2030)

14.1.9. Rest of North America

14.1.9.1. Market Revenue and Forecast, by Drug Class (2017-2030)

14.1.9.2. Market Revenue and Forecast, by Indication (2017-2030)

14.1.9.3. Market Revenue and Forecast, by Type (2017-2030)

14.1.9.4. Market Revenue and Forecast, by Pain Type (2017-2030)

14.1.9.5. Market Revenue and Forecast, by Application (2017-2030)

14.1.9.6. Market Revenue and Forecast, by Distribution Channel (2017-2030)

14.1.9.7. Market Revenue and Forecast, by Route of Administration (2017-2030)

14.2. Europe

14.2.1. Market Revenue and Forecast, by Drug Class (2017-2030)

14.2.2. Market Revenue and Forecast, by Indication (2017-2030)

14.2.3. Market Revenue and Forecast, by Type (2017-2030)

14.2.4. Market Revenue and Forecast, by Pain Type (2017-2030)

14.2.5. Market Revenue and Forecast, by Application (2017-2030)

14.2.6. Market Revenue and Forecast, by Distribution Channel (2017-2030)

14.2.7. Market Revenue and Forecast, by Route of Administration (2017-2030)

14.2.8. UK

14.2.8.1. Market Revenue and Forecast, by Drug Class (2017-2030)

14.2.8.2. Market Revenue and Forecast, by Indication (2017-2030)

14.2.8.3. Market Revenue and Forecast, by Type (2017-2030)

14.2.8.4. Market Revenue and Forecast, by Pain Type (2017-2030)

14.2.8.5. Market Revenue and Forecast, by Application (2017-2030)

14.2.8.6. Market Revenue and Forecast, by Distribution Channel (2017-2030)

14.2.8.7. Market Revenue and Forecast, by Route of Administration (2017-2030)

14.2.9. Germany

14.2.9.1. Market Revenue and Forecast, by Drug Class (2017-2030)

14.2.9.2. Market Revenue and Forecast, by Indication (2017-2030)

14.2.9.3. Market Revenue and Forecast, by Type (2017-2030)

14.2.9.4. Market Revenue and Forecast, by Pain Type (2017-2030)

14.2.9.5. Market Revenue and Forecast, by Application (2017-2030)

14.2.9.6. Market Revenue and Forecast, by Distribution Channel (2017-2030)

14.2.9.7. Market Revenue and Forecast, by Route of Administration (2017-2030)

14.2.10. France

14.2.10.1. Market Revenue and Forecast, by Drug Class (2017-2030)

14.2.10.2. Market Revenue and Forecast, by Indication (2017-2030)

14.2.10.3. Market Revenue and Forecast, by Type (2017-2030)

14.2.10.4. Market Revenue and Forecast, by Pain Type (2017-2030)

14.2.10.5. Market Revenue and Forecast, by Application (2017-2030)

14.2.10.6. Market Revenue and Forecast, by Distribution Channel (2017-2030)

14.2.10.7. Market Revenue and Forecast, by Route of Administration (2017-2030)

14.2.11. Rest of Europe

14.2.11.1. Market Revenue and Forecast, by Drug Class (2017-2030)

14.2.11.2. Market Revenue and Forecast, by Indication (2017-2030)

14.2.11.3. Market Revenue and Forecast, by Type (2017-2030)

14.2.11.4. Market Revenue and Forecast, by Pain Type (2017-2030)

14.2.11.5. Market Revenue and Forecast, by Application (2017-2030)

14.2.11.6. Market Revenue and Forecast, by Distribution Channel (2017-2030)

14.2.11.7. Market Revenue and Forecast, by Route of Administration (2017-2030)

14.3. APAC

14.3.1. Market Revenue and Forecast, by Drug Class (2017-2030)

14.3.2. Market Revenue and Forecast, by Indication (2017-2030)

14.3.3. Market Revenue and Forecast, by Type (2017-2030)

14.3.4. Market Revenue and Forecast, by Pain Type (2017-2030)

14.3.5. Market Revenue and Forecast, by Application (2017-2030)

14.3.6. Market Revenue and Forecast, by Distribution Channel (2017-2030)

14.3.7. Market Revenue and Forecast, by Route of Administration (2017-2030)

14.3.8. India

14.3.8.1. Market Revenue and Forecast, by Drug Class (2017-2030)

14.3.8.2. Market Revenue and Forecast, by Indication (2017-2030)

14.3.8.3. Market Revenue and Forecast, by Type (2017-2030)

14.3.8.4. Market Revenue and Forecast, by Pain Type (2017-2030)

14.3.8.5. Market Revenue and Forecast, by Application (2017-2030)

14.3.8.6. Market Revenue and Forecast, by Distribution Channel (2017-2030)

14.3.8.7. Market Revenue and Forecast, by Route of Administration (2017-2030)

14.3.9. China

14.3.9.1. Market Revenue and Forecast, by Drug Class (2017-2030)

14.3.9.2. Market Revenue and Forecast, by Indication (2017-2030)

14.3.9.3. Market Revenue and Forecast, by Type (2017-2030)

14.3.9.4. Market Revenue and Forecast, by Pain Type (2017-2030)

14.3.9.5. Market Revenue and Forecast, by Application (2017-2030)

14.3.9.6. Market Revenue and Forecast, by Distribution Channel (2017-2030)

14.3.9.7. Market Revenue and Forecast, by Route of Administration (2017-2030)

14.3.10. Japan

14.3.10.1. Market Revenue and Forecast, by Drug Class (2017-2030)

14.3.10.2. Market Revenue and Forecast, by Indication (2017-2030)

14.3.10.3. Market Revenue and Forecast, by Type (2017-2030)

14.3.10.4. Market Revenue and Forecast, by Pain Type (2017-2030)

14.3.10.5. Market Revenue and Forecast, by Application (2017-2030)

14.3.10.6. Market Revenue and Forecast, by Distribution Channel (2017-2030)

14.3.10.7. Market Revenue and Forecast, by Route of Administration (2017-2030)

14.3.11. Rest of APAC

14.3.11.1. Market Revenue and Forecast, by Drug Class (2017-2030)

14.3.11.2. Market Revenue and Forecast, by Indication (2017-2030)

14.3.11.3. Market Revenue and Forecast, by Type (2017-2030)

14.3.11.4. Market Revenue and Forecast, by Pain Type (2017-2030)

14.3.11.5. Market Revenue and Forecast, by Application (2017-2030)

14.3.11.6. Market Revenue and Forecast, by Distribution Channel (2017-2030)

14.3.11.7. Market Revenue and Forecast, by Route of Administration (2017-2030)

14.4. MEA

14.4.1. Market Revenue and Forecast, by Drug Class (2017-2030)

14.4.2. Market Revenue and Forecast, by Indication (2017-2030)

14.4.3. Market Revenue and Forecast, by Type (2017-2030)

14.4.4. Market Revenue and Forecast, by Pain Type (2017-2030)

14.4.5. Market Revenue and Forecast, by Application (2017-2030)

14.4.6. Market Revenue and Forecast, by Distribution Channel (2017-2030)

14.4.7. Market Revenue and Forecast, by Route of Administration (2017-2030)

14.4.8. GCC

14.4.8.1. Market Revenue and Forecast, by Drug Class (2017-2030)

14.4.8.2. Market Revenue and Forecast, by Indication (2017-2030)

14.4.8.3. Market Revenue and Forecast, by Type (2017-2030)

14.4.8.4. Market Revenue and Forecast, by Pain Type (2017-2030)

14.4.8.5. Market Revenue and Forecast, by Application (2017-2030)

14.4.8.6. Market Revenue and Forecast, by Distribution Channel (2017-2030)

14.4.8.7. Market Revenue and Forecast, by Route of Administration (2017-2030)

14.4.9. North Africa

14.4.9.1. Market Revenue and Forecast, by Drug Class (2017-2030)

14.4.9.2. Market Revenue and Forecast, by Indication (2017-2030)

14.4.9.3. Market Revenue and Forecast, by Type (2017-2030)

14.4.9.4. Market Revenue and Forecast, by Pain Type (2017-2030)

14.4.9.5. Market Revenue and Forecast, by Application (2017-2030)

14.4.9.6. Market Revenue and Forecast, by Distribution Channel (2017-2030)

14.4.9.7. Market Revenue and Forecast, by Route of Administration (2017-2030)

14.4.10. South Africa

14.4.10.1. Market Revenue and Forecast, by Drug Class (2017-2030)

14.4.10.2. Market Revenue and Forecast, by Indication (2017-2030)

14.4.10.3. Market Revenue and Forecast, by Type (2017-2030)

14.4.10.4. Market Revenue and Forecast, by Pain Type (2017-2030)

14.4.10.5. Market Revenue and Forecast, by Application (2017-2030)

14.4.10.6. Market Revenue and Forecast, by Distribution Channel (2017-2030)

14.4.10.7. Market Revenue and Forecast, by Route of Administration (2017-2030)

14.4.11. Rest of MEA

14.4.11.1. Market Revenue and Forecast, by Drug Class (2017-2030)

14.4.11.2. Market Revenue and Forecast, by Indication (2017-2030)

14.4.11.3. Market Revenue and Forecast, by Type (2017-2030)

14.4.11.4. Market Revenue and Forecast, by Pain Type (2017-2030)

14.4.11.5. Market Revenue and Forecast, by Application (2017-2030)

14.4.11.6. Market Revenue and Forecast, by Distribution Channel (2017-2030)

14.4.11.7. Market Revenue and Forecast, by Route of Administration (2017-2030)

14.5. Latin America

14.5.1. Market Revenue and Forecast, by Drug Class (2017-2030)

14.5.2. Market Revenue and Forecast, by Indication (2017-2030)

14.5.3. Market Revenue and Forecast, by Type (2017-2030)

14.5.4. Market Revenue and Forecast, by Pain Type (2017-2030)

14.5.5. Market Revenue and Forecast, by Application (2017-2030)

14.5.6. Market Revenue and Forecast, by Distribution Channel (2017-2030)

14.5.7. Market Revenue and Forecast, by Route of Administration (2017-2030)

14.5.8. Brazil

14.5.8.1. Market Revenue and Forecast, by Drug Class (2017-2030)

14.5.8.2. Market Revenue and Forecast, by Indication (2017-2030)

14.5.8.3. Market Revenue and Forecast, by Type (2017-2030)

14.5.8.4. Market Revenue and Forecast, by Pain Type (2017-2030)

14.5.8.5. Market Revenue and Forecast, by Application (2017-2030)

14.5.8.6. Market Revenue and Forecast, by Distribution Channel (2017-2030)

14.5.8.7. Market Revenue and Forecast, by Route of Administration (2017-2030)

14.5.9. Rest of LATAM

14.5.9.1. Market Revenue and Forecast, by Drug Class (2017-2030)

14.5.9.2. Market Revenue and Forecast, by Indication (2017-2030)

14.5.9.3. Market Revenue and Forecast, by Type (2017-2030)

14.5.9.4. Market Revenue and Forecast, by Pain Type (2017-2030)

14.5.9.5. Market Revenue and Forecast, by Application (2017-2030)

14.5.9.6. Market Revenue and Forecast, by Distribution Channel (2017-2030)

14.5.9.7. Market Revenue and Forecast, by Route of Administration (2017-2030)

Chapter 15. Company Profiles

15.1. Abbott

15.1.1. Company Overview

15.1.2. Product Offerings

15.1.3. Financial Performance

15.1.4. Recent Initiatives

15.2. Pfizer Inc.

15.2.1. Company Overview

15.2.2. Product Offerings

15.2.3. Financial Performance

15.2.4. Recent Initiatives

15.3. Eli Lilly & Company

15.3.1. Company Overview

15.3.2. Product Offerings

15.3.3. Financial Performance

15.3.4. Recent Initiatives

15.4. Endo International plc

15.4.1. Company Overview

15.4.2. Product Offerings

15.4.3. Financial Performance

15.4.4. Recent Initiatives

15.5. F. Hoffmann-La Roche AG

15.5.1. Company Overview

15.5.2. Product Offerings

15.5.3. Financial Performance

15.5.4. Recent Initiatives

15.6. Bausch Health Companies Inc.

15.6.1. Company Overview

15.6.2. Product Offerings

15.6.3. Financial Performance

15.6.4. Recent Initiatives

15.7. Merck & Co. Inc.

15.7.1. Company Overview

15.7.2. Product Offerings

15.7.3. Financial Performance

15.7.4. Recent Initiatives

15.8. AbbVie Inc.

15.8.1. Company Overview

15.8.2. Product Offerings

15.8.3. Financial Performance

15.8.4. Recent Initiatives

15.9. Novartis AG

15.9.1. Company Overview

15.9.2. Product Offerings

15.9.3. Financial Performance

15.9.4. Recent Initiatives

15.10. Johnson & Johnson Private Limited

15.10.1. Company Overview

15.10.2. Product Offerings

15.10.3. Financial Performance

15.10.4. Recent Initiatives

Chapter 16. Research Methodology

16.1. Primary Research

16.2. Secondary Research

16.3. Assumptions

Chapter 17. Appendix

17.1. About Us

17.2. Glossary of Terms

Thanks for reading you can also get individual chapter-wise sections or region-wise report versions such as North America, Europe, or the Asia Pacific.

Download Access to a Free Copy of Our Latest Sample Report@ https://www.precedenceresearch.com/sample/2282

Contact Us:

Mr. Alex

Sales Manager

Call: +1 9197 992 333

Email: sales@precedenceresearch.com

Web: https://www.precedenceresearch.com